Why the study?
Does propafenone suppress ventricular ectopy and what are its pharmacokinetic and pharmacodynamic properties in patients with ventricular arrhythmia?
Population
169 subjects with ventricular arrhythmia
Comparison
Propafenone 337.5, 450, 675, or 900 mg/day vs Placebo
Design
RCT, randomized to one of five parallel treatment groups, double-blind
Authors
Loading...
Nonlinear kinetics warrant cautious titration to limit conduction slowing; extends PK/PD characterization for propafenone in ventricular arrhythmia.
Does propafenone suppress ventricular ectopy and what are its pharmacokinetic and pharmacodynamic properties in patients with ventricular arrhythmia?
Propafenone demonstrates nonlinear pharmacokinetics and concentration-dependent suppression of ventricular arrhythmias, alongside dose-dependent ECG interval prolongation.
Zoble et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: